4.2 Post-Exposure Management Protocols

Key Takeaways

  • Immediate post-exposure management for bloodborne pathogen exposure requires washing needle sticks and wounds with soap and water and flushing mucous membranes with water or saline for 15 minutes.
  • HIV post-exposure prophylaxis (PEP) consists of a 3-drug antiretroviral regimen that should be initiated as soon as possible, ideally within 2 hours of exposure, and continued for 28 days.
  • Hepatitis B post-exposure prophylaxis depends on source HBsAg status and employee vaccine response; unvaccinated or non-responder employees exposed to HBsAg-positive blood require HBIG and HBV vaccination.
  • Routine PEP is not recommended for Hepatitis C exposures; management relies on baseline testing and follow-up HCV RNA testing at 3–6 weeks, with direct-acting antivirals initiated if infection develops.
  • Non-bloodborne post-exposure management includes macrolide prophylaxis for pertussis, post-exposure MMR/varicella vaccination or immune globulin for measles/varicella, and two-step post-exposure testing for tuberculosis.
Last updated: July 2026

Post-Exposure Management Protocols

Occupational exposures to bloodborne pathogens (BBP) and communicable infectious diseases represent high-priority medical emergencies in healthcare facilities. Infection preventionists, occupational health providers, and clinical supervisors must execute immediate, standardized management protocols to minimize transmission risks following an exposure.


Exposure Definition & Immediate First Aid

An occupational exposure is defined as a percutaneous injury (e.g., needlestick or cut with a contaminated sharp instrument), contact of mucous membranes (eyes, nose, mouth), or contact of non-intact skin (dermatitis, chapped, abraded skin) with blood, tissue, or potentially infectious body fluids.

Infectious vs. Non-Infectious Body Fluids

  • Potentially Infectious for BBP: Blood, semen, vaginal secretions, cerebrospinal fluid (CSF), synovial fluid, pleural fluid, peritoneal fluid, pericardial fluid, and amniotic fluid.
  • Non-Infectious for BBP (unless visibly bloody): Tears, sweat, urine, feces, saliva, vomitus, and nasal secretions.

Immediate First Aid Measures

  1. Percutaneous Injuries & Skin Cuts: Wash the wound thoroughly with soap and water immediately. Do NOT squeeze or milk the wound, and do NOT apply harsh caustic antiseptics (such as bleach or concentrated iodine) into the wound.
  2. Mucous Membrane Splashes: Flush the affected eyes, nose, or mouth with copious amounts of clean water or sterile saline for at least 15 minutes.
  3. Reporting: Report the exposure incident immediately to occupational health or the emergency department supervisor.

Source Patient Evaluation

Immediate efforts must be made to identify and evaluate the source patient:

  • Obtain informed consent (per state law) and rapidly test source patient blood for:
    • HIV: 4th-generation HIV antigen/antibody immunoassay.
    • Hepatitis B: Hepatitis B surface antigen (HBsAg).
    • Hepatitis C: Hepatitis C virus antibody (anti-HCV) with reflex HCV RNA.
  • Critical Clinical Rule: Post-exposure prophylaxis (PEP) for the exposed employee must never be delayed while awaiting laboratory results from the source patient.

Bloodborne Pathogen PEP Algorithms

1. Human Immunodeficiency Virus (HIV) PEP

  • Indications: Significant percutaneous or mucous membrane exposure to blood or infectious fluids from a known HIV-positive source or a high-risk unknown source.
  • Standard 3-Drug PEP Regimen: Preferred combination includes 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus an integrase strand transfer inhibitor (INSTI):
    • Tenofovir disoproxil fumarate (TDF) $300 \text{ mg}$ + Emtricitabine (FTC) $200 \text{ mg}$ once daily, PLUS
    • Raltegravir $400 \text{ mg}$ twice daily OR Dolutegravir $50 \text{ mg}$ once daily.
  • Timing & Duration: PEP must be initiated as soon as possible, ideally within 2 hours post-exposure. Efficacy drops significantly if delayed beyond 72 hours. Total duration of treatment is 28 days.
  • Follow-up Testing Schedule: Baseline HIV testing, followed by repeat testing at 6 weeks and 4 months post-exposure (or 12 weeks post-exposure if using a 4th-generation Ag/Ab combination assay).

2. Hepatitis B Virus (HBV) PEP Protocol

Post-exposure management for HBV depends on the source patient's HBsAg status and the exposed employee's vaccination and anti-HBs response status:

Exposed Employee StatusSource HBsAg PositiveSource HBsAg NegativeSource Unknown / Untested
Vaccinated Responder (anti-HBs $\ge 10 \text{ mIU/mL}$)No treatment requiredNo treatment requiredNo treatment required
Vaccinated Non-Responder (anti-HBs $< 10 \text{ mIU/mL}$ after 2 series)Administer 2 doses HBIG (1 mo apart) OR 1 dose HBIG + re-vaccinationNo treatment requiredTreat as if source is positive if high-risk source
Unvaccinated / Incomplete SeriesAdminister 1 dose HBIG ($0.06 \text{ mL/kg}$) immediately + initiate HBV vaccine seriesComplete HBV vaccine seriesComplete HBV vaccine series
Vaccinated, Unknown ResponseTest anti-HBs immediately. If $\ge 10$, no PEP. If $<10$, give 1 dose HBIG + vaccine boosterNo treatment requiredTest anti-HBs. If $<10$, administer vaccine booster

Note: HBIG should be administered as soon as possible, ideally within 24 hours post-exposure (maximum window: 7 days).

3. Hepatitis C Virus (HCV) Management Protocol

  • PEP Recommendation: No post-exposure prophylaxis is recommended for HCV exposure. Neither immune globulin nor direct-acting antiviral (DAA) medications are approved for immediate post-exposure prophylaxis.
  • Baseline & Follow-up Testing:
    • Baseline testing of exposed employee: anti-HCV antibody, HCV RNA, and baseline ALT.
    • Early detection monitoring: Perform HCV RNA testing at 3 to 6 weeks post-exposure.
    • Confirmation testing: Perform anti-HCV testing at 4 to 6 months post-exposure (with reflex HCV RNA if positive).
  • Treatment Protocol: If acute HCV infection is confirmed (positive HCV RNA), refer the employee to a specialist for Direct-Acting Antiviral (DAA) therapy. DAA therapy yields cure rates (sustained virologic response) $> 95%$.

Non-Bloodborne Pathogen Post-Exposure Protocols

Occupational health must manage exposures to airborne, droplet, and contact pathogens effectively:

Pathogen / DiseasePEP / Prophylactic InterventionTiming of InterventionWork Restriction Window
Tuberculosis (TB)Baseline IGRA/TST; repeat IGRA/TST at 8–10 weeks post-exposureBaseline immediately; repeat at 8–10 wkNo restriction unless active TB disease suspected
Varicella (VZV)Varicella vaccine (healthy non-immune) or VARIZIG (high-risk/pregnant)Vaccine within 3–5 days; VARIZIG within 96 hr (up to 10 days)Exclude non-immune HCP from day 8 to day 21 post-exposure
Measles (Rubeola)MMR vaccine (non-immune)Administer within 72 hours post-exposureExclude non-immune HCP from day 5 to day 21 post-exposure
PertussisOral Azithromycin ($500 \text{ mg}$ day 1, $250 \text{ mg}$ days 2–5) regardless of Tdap statusInitiate as soon as exposure identifiedRestrict symptomatic HCP until 5 days of antibiotics completed
ScabiesTopical Permethrin 5% cream applied neck down overnightApply single treatment immediatelyRestrict from care until 24 hours after treatment applied
Test Your Knowledge

A phlebotomist sustains a deep percutaneous needle stick from a needle contaminated with blood from a known HIV-positive patient with a high viral load. What is the recommended timeline for initiating HIV post-exposure prophylaxis (PEP) and the duration of treatment?

A
B
C
D
Test Your Knowledge

An unvaccinated environmental services worker sustains a hollow-bore needlestick injury from a source patient who tests positive for Hepatitis B surface antigen (HBsAg). What post-exposure prophylaxis is required for this employee?

A
B
C
D
Test Your Knowledge

A nurse is exposed to blood from a patient with active chronic Hepatitis C virus (HCV) infection via a deep scalpel wound. What is the correct post-exposure management strategy for this nurse?

A
B
C
D
Test Your Knowledge

An intensive care unit nurse is exposed to an infant with laboratory-confirmed pertussis without wearing a mask. The nurse received a Tdap booster 2 years ago. What post-exposure management is recommended?

A
B
C
D